StockWatch
·
Q2 FY-2027 RESULTS · VENUSREM

Venus Remedies Q2 FY27: PAT +27% YoY to ₹25.65 Cr, margins expand, revenue beats Street

PAT +27.42% YoY · revenue +13.5% · margins expanding · beat vs street

Q2 FY27 resultsVENUSREMVENUS REMEDIES LTD.26 Oct 2026 · 3 min read
Revenue

₹218.76 Cr

+13.5% YoY

PAT (consolidated)

₹25.65 Cr

+27.42% YoY

Net margin

11.7%

+1.3pp YoY

EPS

₹19.19

Venus Remedies' consolidated PAT (primary basis) rose 27.4% YoY to ₹25.65 Cr on revenue of ₹218.76 Cr, up 13.5% YoY — profit growing roughly twice as fast as the topline, the clearest sign of margin expansion this quarter. Against our pre-result preview, which flagged ₹150–180 Cr revenue and ₹25–32 Cr PAT as the on-plan range alongside a Street consensus of BUY (9 analysts: 5 buy, 3 strong buy, 1 hold; ₹2,350 target vs the ₹1,592 pre-result close), revenue came in well above the top end of that band while PAT landed mid-range — a clean beat on scale and an in-line print on profitability.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹218.76 Cr+22.3%+13.5%
Expenses₹185.8 Cr+22.7%+10.6%
PAT₹25.65 Cr+11.67%+27.42%
Net margin11.7%-1pp+1.3pp
EPS₹19.19+11.7%+27.4%

On margins, operating margin (PBT + depreciation − other income, over operating revenue) widened to 19.43% from 16.06% a year ago, and net margin to 11.70% from 10.35%, as operating leverage on the larger revenue base outpaced higher employee costs (₹26.53 Cr vs ₹22.97 Cr YoY) and R&D spend (₹5.98 Cr vs ₹4.35 Cr). Sequentially, though, NPM eased from 12.66% in Q1 FY27 even as OPM barely moved (19.12% to 19.43%) — a mild QoQ softening on the bottom line that the YoY comparison, which is the primary read here, screens past.

₹
1,370.81,497.761,624.731,751.691,878.651,46507-2308-1409-0709-3010-26Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹1,465, down 11% over the past month of trading.

₹ Cr
017.7335.4653.199.6Q1 FY26rev ₹132 Cr20.13Q2 FY26rev ₹193 Cr25.58Q3 FY26rev ₹180 Cr47.49Q4 FY26rev ₹259 Cr22.97Q1 FY27rev ₹179 Cr25.65Q2 FY27rev ₹219 Cr
Quarterly consolidated PAT, ₹ Crore

For context: this is the second-highest quarterly PAT of the last 6 quarters.

Management issued no formal FY27 guidance in this filing or on record, so the print can only be graded against the Street's own expectation band, which it cleared on revenue. The October 16 disclosure of five new marketing authorisations across four countries lines up with the international-registration driver our preview flagged, though the statement itself carries no country-level revenue split to size that contribution this quarter. Auditors carried an emphasis-of-matter (opinion unmodified) on ₹28.60 Cr of share-application money still pending allotment at wholly-owned German subsidiary Venus Pharma GmbH, which management ties to an ongoing European restructuring; that unit posted a ₹5.84 Cr net loss on ₹3.64 Cr revenue for the half year, which is why consolidated PAT (₹25.65 Cr, EPS ₹19.19) runs about 11% below standalone PAT (₹28.96 Cr, EPS ₹21.66) — worth flagging since readers will encounter the higher standalone number elsewhere.

  • W1

    Whether NPM recovers from its QoQ dip (12.66% in Q1 FY27 to 11.70% in Q2) even as OPM holds near 19.4%

  • W2

    Whether the 5 new marketing authorisations (4 countries, announced Oct 16) convert into bookable international revenue next quarter

  • W3

    Progress on Venus Pharma GmbH's European restructuring and whether its ₹5.84 Cr half-year loss narrows

Informational and educational content only. Not investment advice.